We already know from two-year follow-up studies of patients who have taken injectable GLP-1 drugs for at least six months that net weight loss in the real world is as little as 4.7% for many reasons, including poor adherence as a result of side effects, supply and affordability
AR affects approximately 10-40% of people globally [4], damaging labor productivity and causing economic losses of 30 to 50 billion euros per year in the European Union [5]
Incretin-based therapies operate on a different axis: they exert modest effects on the lipid panel but substantial effects on systemic inflammation, vascular biology, body composition, blood pressure, and renal hemodynamics [2], [18]
Since then, it has been dramatically used, especially following its approval for weight loss and its demonstrated efficacy in reducing cardiovascular risks and kidney protective mechanisms in diabetic patients
On top of this, adherence to GLP-1 treatments isn't exactly promising, either
The brain is not one wire running through everything